ETF Managers Group’s Galmed Pharmaceuticals GLMD Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2020
Q4
Sell
-50
Closed -$254K 628
2020
Q3
$254K Buy
50
+3
+6% +$19.6K 0.01% 547
2020
Q2
$324K Buy
47
+18
+62% +$121K 0.01% 370
2020
Q1
$143K Buy
29
+3
+12% +$22.8K 0.01% 500
2019
Q4
$216K Sell
26
-6
-19% -$41.2K 0.01% 511
2019
Q3
$228K Buy
32
+1
+3% +$8.03K 0.01% 348
2019
Q2
$282K Buy
31
+8
+35% +$82.5K 0.01% 292
2019
Q1
$274K Sell
23
-1
-4% -$11.6K 0.01% 269
2018
Q4
$237K Buy
24
+8
+50% +$112K 0.01% 282
2018
Q3
$316K Buy
+16
New +$300K 0.01% 231
2018
Q2
Sell
-10
Closed -$76K 533
2018
Q1
$76K Buy
10
+1
+11% +$11.7K ﹤0.01% 401
2017
Q4
$119K Buy
+9
New +$106K 0.01% 225

Other funds holding GLMD

ETF Managers Group's GLMD Position: Q4 2020 in Review

ETF Managers Group sold out of Galmed Pharmaceuticals (GLMD) in Q4 2020, closing a stake of 50 shares — an estimated $254K sold.

ETF Managers Group first reported a position in GLMD in Q4 2017 and held it in 11 quarters. The position peaked at $324K in Q2 2020. 18 funds tracked by Wall St. Rank hold GLMD as of Q4 2020.

  • ETF Managers Group reported no remaining Galmed Pharmaceuticals position as of Q4 2020 after selling out during the quarter.
  • ETF Managers Group sold 50 Galmed Pharmaceuticals shares in Q4 2020, an estimated $254K.
  • ETF Managers Group first reported a position in Galmed Pharmaceuticals in Q4 2017 and held it in 11 quarters.
  • ETF Managers Group's Galmed Pharmaceuticals position peaked at $324K in Q2 2020.
  • 18 funds tracked by Wall St. Rank held Galmed Pharmaceuticals as of Q4 2020.

Based on ETF Managers Group's 13F filing for Q4 2020, filed 16 Feb 2021.